Company: CERO
Filing Date: 2025-07-18
Form Type: 8-K
Source: 0001213900-25-065655
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-18
Form: 8-K
Item: Item 3.02
Chunk 0
---
Item 3.02 Unregistered Sales of Equity Securities.

As previously reported on the Current Report on
Form 8-K filed with the Securities and Exchange Commission (the “ SEC”) on April 22, 2025 and June 30, 2025, CERo Therapeutics
Holdings, Inc. (the “ Company”) entered into the Securities Purchase Agreement on April 21, 2025, as amended by that certain
Amendment No. 1 to the Securities Purchase Agreement on June 25, 2025 (collectively, the “ Securities Purchase Agreement”)
with certain institutional investors (the “ Investors”), pursuant to which the Company agreed to issue and sell, in one or
more closings, up to 10,000 shares of the Company’s Series D convertible preferred stock, par value $0.0001 per share (the “ Series
D Preferred Stock”), which are convertible into shares of the Company’s common stock, par value $0.0001 per share (the “ Common
Stock”), in a private placement offering. As previously reported on the Current Report on Form 8-K filed with the SEC on June 6,
2025 and on June 30, 2025, the Company completed Additional Closings (as defined in the Securities Purchase Agreement) on June 5, 2025,
pursuant to which the Company sold an additional 938 shares of Series D Preferred Stock for gross proceeds of approximately $750,400 and
on June 25, 2025, pursuant to which the Company sold an additional 2,315 shares of the Series D Preferred Stock for gross proceeds of
approximately $1,852,000.

On July 18, 2025, pursuant to the Securities Purchase
Agreement, the Company and certain Investors, mutually agreed to effect, and effected, an Additional Closing, with respect to 497 additional
shares of Series D Preferred Stock for gross proceeds of approximately $397,600. The rights, preferences and privileges of the Series
D Preferred Stock are set forth in the certificate of designations of rights and preferences of the Series D Preferred Stock (the “ Certificate
of Designations”), filed with the Secretary of State of the State of Delaware on April 22, 2025. The offering and sale of the shares
of Series D Preferred Stock were issued and, upon conversion of the Series D Preferred Stock, the shares of Common Stock underlying the
Series D Preferred Stock will be issued, in each case,